.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent research identifies a significant link between uric acid osteoporosis risk. Scientists analyzed data from the 2015-2020 NHANES and conducted Mendelian randomization to understand how serum uric acid (SUA) influences bone health. Consequently, they found that higher SUA levels correlate with a reduced risk of osteoporosis.
The cross-sectional study included 6,020 participants. Individuals in the highest SUA quartiles showed a 49% lower risk compared to those in the lowest quartile. Furthermore, restricted cubic spline analysis revealed an L-shaped relationship. The study pinpointed a turning point at approximately 5.3 mg/dL. This suggests that maintaining moderate SUA levels might provide a protective effect against bone loss.
Subgroup analysis indicated that sex, race, and diabetes status are essential modifiers. Additionally, the Mendelian randomization analysis explored whether these findings represent a causal relationship. Although SUA is often associated with gout, its antioxidant properties may actually benefit bone metabolism. Therefore, physicians should consider these nuances when managing patients with metabolic disorders. Moreover, the study highlights the need for balanced clinical strategies regarding urate-lowering therapies.
Serum uric acid may act as an antioxidant in the blood. This helps protect bone mineral density and potentially reduces the risk of osteoporosis.
The study identified an L-shaped association. It showed a significant turning point around 5.3 mg/dL, where the risk of osteoporosis began to decrease significantly.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Liu QP et al. Association between serum uric acid levels and osteoporosis risk: evidence from a cross-sectional study and Mendelian randomization analysis. Clin Rheumatol. 2026 Feb 14. doi: 10.1007/s10067-026-07986-3. PMID: 41689734.
Wang H et al. Association of Serum Uric Acid Level With Bone Mineral Density and the Risk of Osteoporosis: A Dose-Response Meta-Analysis. Int J Rheum Dis. 2025 Jan 15. doi: 10.1111/1756-185X.70013. PMID: 39744825.
Song S et al. Value of serum uric acid in a risk prediction model for postmenopausal osteoporosis. Front Endocrinol (Lausanne). 2025 Aug 09;16:1434602. doi: 10.3389/fendo.2025.1434602.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A large-scale study reveals that higher serum uric acid levels are associated with a 49% lower risk of osteoporosis, suggesting a protective role in bone he...
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
